AcelRx Pharmaceuticals says ARX-04 phase 3 trial met primary endpoint
Tuesday, August 16, 2016
AcelRx Pharmaceuticals Inc Overall ARX-04 was well tolerated in study, with 79% of patients reporting no adverse events. Topline results from single-arm, open-label phase 3 sap302 trial which assessed ARX-04 in patients with pain related to trauma or injury.
AcelRx Pharmaceuticals' ARX-04 phase 3 trial met its primary endpoint, reduced pain intensity in er patients with moderate-to-severe acute pain.
Most common adverse events reported in study occurred with single-digit rates.
Source : reuters.com
